Pfizer has emerged victorious in a ten billion dollar bidding contest to acquire the weight-loss biotechnology firm Metsera, concluding an intense takeover competition after the manufacturer of Ozempic attempted to intervene in an initial proposal. Following a week of competitive offers initiated by an uninvited bid from Novo Nordisk in late October 2025, Metsera disclosed late on Friday that it elected to advance with Pfizer due to regulatory apprehensions raised by the United States antitrust authority regarding Novo’s proposition.
Pfizer’s revised agreement to purchase Metsera appraises the biotechnology enterprise at up to two point seven billion dollars more than a prior arrangement from September 2025. Shareholders of Metsera will obtain sixty-five dollars and fifty cents per share in immediate cash, supplemented by an additional twenty dollars and sixty-five cents per share contingent upon achieving specified clinical trial benchmarks. As reported by CNBC, Metsera received communication from the United States Federal Trade Commission highlighting issues with the atypical configuration of Novo’s offer, prompting the conclusion that it entailed excessively elevated legal and regulatory hazards.
Novo Nordisk, in conjunction with Eli Lilly, holds a commanding position in the obesity treatment sector through its medications Ozempic and Wegovy. The unconventional bifurcated structure of Novo’s proposal, which promised to distribute over seven billion dollars to Metsera’s investors nearly instantly via a distribution, incited Pfizer to initiate legal proceedings to obstruct the merger and elicited cautions from the Federal Trade Commission that it might contravene competition regulations. In correspondence to Metsera’s governing body earlier in the week, the commission indicated it could mandate the restitution of any preliminarily disbursed funds.
Metsera further noted on Friday that among the perils of Novo’s arrangement was the possibility that the preliminary distribution might never materialise or could face subsequent contestation or revocation. Established merely three years prior and employing one hundred staff, Metsera possesses one of the most auspicious arrays of investigational obesity therapies, encompassing a prolonged-duration monthly injectable, an oral weight-loss formulation, and compounds employing an alternative biochemical pathway known as Amylin. According to Pfizer, the proposed acquisition will incorporate four highly differentiated clinical-stage incretin and amylin programmes into its portfolio, enhancing its capabilities in addressing obesity and related metabolic conditions.
The acquisition skirmish featured reciprocal challenges from Pfizer and Novo Nordisk. Under its recently appointed chief executive, Novo Nordisk seeks to counteract a fifty per cent depreciation in its equity value as stakeholders apprehend it is being outpaced by Eli Lilly in the obesity medication contest. Concurrently, Pfizer endeavours to establish a presence in this profitable domain after its internally developed remedy faltered in experimental evaluations earlier in 2025. As detailed by The Wall Street Journal, Pfizer lodged an antitrust complaint to impede Novo Nordisk’s acquisition of Metsera, asserting that the merger would consolidate Novo’s dominance in the market.
During an engagement at the White House publicising a pharmaceutical pricing accord on Thursday, Novo’s leader remarked that his firm had surpassed Pfizer’s offer and encouraged the American competitor to elevate its proposal, asserting it was a competitive marketplace and unrelated to regulatory oversight. On a prior earnings discussion, Pfizer’s chief executive critiqued Novo’s Metsera proposal as an unlawful manoeuvre by an overseas entity to circumvent competition statutes, exploiting a governmental hiatus.
Novo Nordisk declared on Saturday that it would refrain from augmenting its offer for the obesity-centric biotechnology due to its adherence to fiscal prudence and stakeholder interests. The Danish pharmaceutical entity supplemented that it maintains the configuration of the prospective merger complies with antitrust statutes. The Federal Trade Commission earlier in the month granted Pfizer’s arrangement an expedited termination notification, effectively expediting it through competition scrutiny, an uncommon measure amidst the administrative suspension.
Pfizer’s agreement will be subjected to an investor ballot on 13 November 2025. As noted by The New York Times, the announcement signifies the conclusion of the bidding contest for Metsera, valued at ten billion dollars, reinforcing Pfizer’s strategic pivot towards innovative therapies in high-growth areas like obesity management. This transaction not only bolsters Pfizer’s pipeline but also intensifies competition in a market projected to exceed one hundred billion dollars annually by 2030, driven by escalating global obesity rates and demand for effective treatments.